Beijing SL Pharmaceutical Co., Ltd. (SHE:002038)

Beijing SL Pharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	411.96	683.83	595.04	827.84	663.48
Short-Term Investments	-	785.86	713.36	646.23	605.63
Trading Asset Securities	480.86	608.56	144.91	162.36	173.81
Cash & Short-Term Investments	892.81	2,078	1,453	1,636	1,443
Cash Growth	-57.04%	43.00%	-11.19%	13.41%	-24.62%
Accounts Receivable	105.79	200.57	254.86	357.56	466.08
Other Receivables	15.65	35.25	31.35	21.6	2.9
Receivables	121.44	235.82	286.2	379.16	468.98
Inventory	246.33	144.46	136.82	124.83	112.03
Other Current Assets	1,228	181.45	121.34	157.31	183.4
Total Current Assets	2,489	2,640	1,998	2,298	2,207
Property, Plant & Equipment	514.24	503.34	527.3	604.01	589.16
Long-Term Investments	1,231	1,182	1,798	1,404	1,251
Other Intangible Assets	678.58	693.77	526.36	479.46	423.38
Long-Term Deferred Tax Assets	69.52	-	39.5	27.65	25.35
Long-Term Deferred Charges	519	451.89	454.42	394.72	291.84
Other Long-Term Assets	477.35	806.44	532.22	553.25	606.28
Total Assets	5,979	6,278	5,876	5,760	5,395
Accounts Payable	122.29	250.76	176.18	191.4	179.93
Accrued Expenses	42.95	46.93	30.32	31.8	25.23
Short-Term Debt	-	-	-	-	5.51
Current Portion of Leases	-	-	-	0.25	-
Current Income Taxes Payable	3.49	0	2.61	4.48	4.28
Current Unearned Revenue	70.51	15.29	27.87	13.33	10.01
Other Current Liabilities	50.18	60.34	51.85	83.71	90.02
Total Current Liabilities	289.41	373.33	288.83	324.96	314.98
Long-Term Leases	-	-	-	2.22	-
Long-Term Unearned Revenue	44	47.04	51.38	56.23	60.97
Long-Term Deferred Tax Liabilities	64.97	47.36	56.39	50.82	34.15
Total Liabilities	398.37	467.72	396.6	434.23	410.09
Common Stock	1,027	1,027	1,027	1,027	1,027
Additional Paid-In Capital	49.62	49.62	43.85	32.58	17.59
Retained Earnings	4,482	4,710	4,396	4,265	3,941
Comprehensive Income & Other	13.47	13.47	0.67	-12.99	-11.68
Total Common Equity	5,572	5,801	5,468	5,311	4,975
Minority Interest	8.2	9.42	11.16	14.73	10.13
Shareholders' Equity	5,581	5,810	5,479	5,326	4,985
Total Liabilities & Equity	5,979	6,278	5,876	5,760	5,395
Total Debt	-	-	-	2.47	5.51
Net Cash (Debt)	892.81	2,078	1,453	1,634	1,437
Net Cash Growth	-57.04%	43.00%	-11.06%	13.67%	-24.75%
Net Cash Per Share	0.84	2.04	1.43	1.57	1.42
Filing Date Shares Outstanding	1,152	1,027	1,027	1,027	1,027
Total Common Shares Outstanding	1,152	1,027	1,027	1,027	1,027
Working Capital	2,199	2,267	1,709	1,973	1,892
Book Value Per Share	4.84	5.65	5.32	5.17	4.84
Tangible Book Value	4,894	5,107	4,942	4,832	4,551
Tangible Book Value Per Share	4.25	4.97	4.81	4.70	4.43
Buildings	-	437.22	430.73	452.32	457.05
Machinery	-	458.48	435.39	415.76	388.59
Construction In Progress	-	56.97	64.75	99.87	67.7

Updated Oct 25, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.